AbbVieRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AbbVie (ABBV) reported revenue of $15.00B in Q1 2026, with SKYRIZI its largest revenue segment at 32%.
AbbVieImmunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
AbbVie (ABBV) is a Drug Manufacturers - General company. Immunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation. It was founded in 2013, is headquartered in North Chicago, IL and employs about 57,000 people.
As of 2026-Q1, AbbVie's revenue breaks down across SKYRIZI (32%), RINVOQ (15%), Other Products (7%), Botox Therapeutic (7%). See the revenue-by-segment chart for the full mix.
Track AbbVie's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups AbbVie in the GLP-1 sector, alongside Pfizer (PFE), Amgen (AMGN), Roche (RHHBY), AstraZeneca (AZN) and Merck & Co. (MRK).
If you are researching AbbVie, also look at Pfizer (PFE), Amgen (AMGN) and Roche (RHHBY). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.